3.0
Dec 21, 2016
Former employee
Port Washington, NY
Recommend
CEO approval
Business outlook
Pros
Great technology build on science
Cons
Upper management ruled by Danaher and several at the top making too many decisions without truly knowing the business. Outside of the Biopharm division, minimal investment, only running the business for cash, most focused on cost cutting.